While TIGIT targeting on NK cells, either alone or in combination with other ICs, leads to the restoration of anti-tumor activities [42], the functional consequence of TIGIT and/or CD96 blockade on ILCs remains unknown. This evidence concerns the gene CD96 and neoplasm.